Publications
650
Citations
27,414
Est. group size
~6
Recurring co-author estimate
Active years
36
Publishing since 1991
Steven M. Devine works in blood and marrow transplantation, focusing on improving outcomes for patients who receive stem cell transplants for blood cancers such as acute myeloid leukemia and lymphoma. His work spans large multi-center clinical trials on donor selection (including mismatched or alternative donors), transplant conditioning regimens, graft-versus-host disease prevention, and monitoring residual disease after transplant. Much of this research is conducted through large collaborative networks that pool data from many transplant centers to guide clinical practice.
Publication output has grown over the last decade, rising from around 20-30 papers per year in 2017-2019 to a sustained pace of about 40 papers per year in 2023-2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Donor-Specific Transplant Outcomes from BMTCTN 1702: A Multi-Center Prospective Biological-Assignment Trial
Blood Advances · 2026
- The MEASURE Genome Atlas: Acute Myeloid Leukemia at diagnosis and complete remission
Blood · 2025
- Current Activity Trends and Outcomes in Hematopoietic Cell Transplantation and Cellular Therapy – A Report from the CIBMTR
Transplantation and Cellular Therapy · 2025
- Measurable residual disease and posttransplantation gilteritinib maintenance for patients with <i>FLT3-ITD</i>–mutated AML
Blood · 2025
- Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Journal of Clinical Oncology · 2025
- Allogeneic Hematopoietic Cell Donor Selection: Contemporary Guidelines from the NMDP/CIBMTR
Transplantation and Cellular Therapy · 2025
- Novel composite health assessment risk model for older allogeneic transplant recipients: BMT-CTN 1704
Blood Advances · 2025
- Primary Results From Blood and Marrow Transplant Clinical Trials Network 1702: Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation
Journal of Clinical Oncology · 2025
- Matched unrelated vs haploidentical donor hematopoietic cell transplantation using posttransplant cyclophosphamide
Blood Advances · 2025
- Impact of transplant conditioning, <i>NPM1</i> mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia
Blood Advances · 2025
- Access to Allogeneic Cell Transplantation Based on Donor Search Prognosis: BMT CTN 1702 Trial
Transplantation and Cellular Therapy · 2025
- CHARM is prognostic of geriatric morbidity and toxicity after allogeneic transplant for older adults: BMT CTN 1704 study
Blood Advances · 2025
- Up-front alternative donor HCT in severe aplastic anemia: gaps and opportunities to translate evidence into practice
Blood Advances · 2025
- Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301/BMT-CTN 1201
Leukemia & lymphoma/Leukemia and lymphoma · 2025
- Measurable residual mutated NPM1 before allogeneic transplant for acute myeloid leukemia
Bone Marrow Transplantation · 2025
- Blood×92
- Transplantation and Cellular Therapy×57
- Biology of Blood and Marrow Transplantation×40
- Blood Advances×22
- Journal of Clinical Oncology×21
- Justin Jiang
Medicine · The Ohio State University
- Hannah Choe
Medicine · The Ohio State University
- Jennifer E. Schwartz
Medicine · Indiana University
- Ayman Saad
Medicine · The Ohio State University
- Marcos de Lima
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile